Cargando…

Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer

Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Takuji, Fujita, Kazutoshi, Matsushita, Makoto, Nonomura, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721573/
https://www.ncbi.nlm.nih.gov/pubmed/31408948
http://dx.doi.org/10.3390/cancers11081153
_version_ 1783448374527131648
author Hayashi, Takuji
Fujita, Kazutoshi
Matsushita, Makoto
Nonomura, Norio
author_facet Hayashi, Takuji
Fujita, Kazutoshi
Matsushita, Makoto
Nonomura, Norio
author_sort Hayashi, Takuji
collection PubMed
description Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance to systemic therapies. Inflammation, which is induced by various factors such as infection, microbiome, obesity, and a high-fat diet, is the major etiology in the development of prostate cancer. Inflammatory cells play important roles in tumor progression. Various immune cells including tumor-associated neutrophils, tumor-infiltrating macrophages, myeloid-derived suppressor cells, and mast cells promote prostate cancer via various intercellular signaling. Further basic studies examining the relationship between the inflammatory process and prostate cancer progression are warranted. Interventions by medications and diets to control systemic and/or local inflammation might be effective therapies for prostate cancer progression. Epidemiological investigations and basic research using human immune cells or mouse models have revealed that non-steroidal anti-inflammatory drugs, metformin, statins, soy isoflavones, and other diets are potential interventions for preventing progression of prostate cancer by suppressing inflammation. It is essential to evaluate appropriate indications and doses of each drug and diet.
format Online
Article
Text
id pubmed-6721573
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67215732019-09-10 Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer Hayashi, Takuji Fujita, Kazutoshi Matsushita, Makoto Nonomura, Norio Cancers (Basel) Review Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance to systemic therapies. Inflammation, which is induced by various factors such as infection, microbiome, obesity, and a high-fat diet, is the major etiology in the development of prostate cancer. Inflammatory cells play important roles in tumor progression. Various immune cells including tumor-associated neutrophils, tumor-infiltrating macrophages, myeloid-derived suppressor cells, and mast cells promote prostate cancer via various intercellular signaling. Further basic studies examining the relationship between the inflammatory process and prostate cancer progression are warranted. Interventions by medications and diets to control systemic and/or local inflammation might be effective therapies for prostate cancer progression. Epidemiological investigations and basic research using human immune cells or mouse models have revealed that non-steroidal anti-inflammatory drugs, metformin, statins, soy isoflavones, and other diets are potential interventions for preventing progression of prostate cancer by suppressing inflammation. It is essential to evaluate appropriate indications and doses of each drug and diet. MDPI 2019-08-12 /pmc/articles/PMC6721573/ /pubmed/31408948 http://dx.doi.org/10.3390/cancers11081153 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hayashi, Takuji
Fujita, Kazutoshi
Matsushita, Makoto
Nonomura, Norio
Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer
title Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer
title_full Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer
title_fullStr Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer
title_full_unstemmed Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer
title_short Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer
title_sort main inflammatory cells and potentials of anti-inflammatory agents in prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721573/
https://www.ncbi.nlm.nih.gov/pubmed/31408948
http://dx.doi.org/10.3390/cancers11081153
work_keys_str_mv AT hayashitakuji maininflammatorycellsandpotentialsofantiinflammatoryagentsinprostatecancer
AT fujitakazutoshi maininflammatorycellsandpotentialsofantiinflammatoryagentsinprostatecancer
AT matsushitamakoto maininflammatorycellsandpotentialsofantiinflammatoryagentsinprostatecancer
AT nonomuranorio maininflammatorycellsandpotentialsofantiinflammatoryagentsinprostatecancer